摘要
目的:归结于生物工程技术的进步,把对肿瘤细胞攻击锁定于表皮生长因子和血管内皮生长因子等靶位,使药物治疗的切入点由细胞水平向分子水平过度,提高肿瘤联合治疗效果,成为肿瘤综合治疗策略。由此应运而生的单克隆抗体药独树一帜,对其研究和评价日趋活跃,本文总结其作用优势和临床评价。方法:采用国内、外文献综述方法。结果及结论:单克隆抗体药疗效确切、特异性强、不良反应和耐药性小,无疑是药学研究领域中的巨大突破。但抗体药难以穿透肿瘤致密的包裹屏障,且价格昂贵,因此,期盼其根治肿瘤的希望依然渺茫,仍有待于大量循证医学研究结果和时间的推移。
OBJECTIVE： Due to the development of biotechnology, epidermal growth factor receptor （EGFR） and vascular endothelial growth factor （VEGF） have been regarded as the target sites in the attack against tumor cells, leading to the shifting of drug treatment focus from cellular level to molecular level and the enhancing of curative effect of combined therapy of tumor, thus a combined therapy of tumor has came into being. From which, the monoclonal antibody agents were produced and which have developed a school of their own and become the subject of intensive research and evaluation; This paper summarized the advantages in efficacy and clinical evaluations of this kind of reagents. METHODS： Literature both home and abroad was reviewed. RESULTS ＆ CONCLUSION： Monoclonal antibodies （mAb） reagents are eutherapeutic and highly specific yet with little toxicity and drug resistance, which are no doubt one of the great breakthroughs in pharmaceutical research. However, because of their difficulty in penetrating the dense encapsulate barrier of tumor and the high prices, there is little as yet little hope for us to expect them to be a radical cure for tumor, which takes time and depends on the research results on evidence based medicine.
出处
《中国医院用药评价与分析》
2007年第1期27-30,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
单克隆抗体
抗肿瘤药
表皮生长因子受体
血管内皮生长因子
进展
评价
monoclonal antibody （Mab）
antitumor drugs
epidermal growth factor receptor
vascular endothelial growth factor
development
evaluation
